Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01133210 · ClinicalTrials.gov registry record · Phase 1

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

A Phase 1 study of Hypertriglyceridemia, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT01133210: Completed Phase 1 study of Hypertriglyceridemia, sponsored by Washington University School of Medicine.

NCT01133210 is a Phase 1 study of Hypertriglyceridemia that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01133210, a Phase 1 study of Hypertriglyceridemia, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation

Primary Outcome

We will compare pre and post-treatment serum triglyceride concentrations in subjects receiving a 12 week course of either Maraviroc or placebo.

Conditions Studied

Interventions

  • OTHER placebo
  • DRUG Maraviroc

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-01
Est. Completion 2012-11
Phase Phase 1

What the finished NCT01133210 record still lists

NCT01133210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01133210 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT01133210 about?

NCT01133210 is a clinical study titled "Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)". The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation

What is the current status of trial NCT01133210?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-01. Estimated completion is 2012-11.

What conditions does trial NCT01133210 study?

This clinical trial studies the following conditions: Hypertriglyceridemia.

What interventions are being tested in trial NCT01133210?

The interventions under investigation include: placebo (OTHER), Maraviroc (DRUG).

Who is sponsoring clinical trial NCT01133210?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01133210 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01133210's enrollment target sits among peer trials

27 21st of 25 higher than 5 of 25 other Hypertriglyceridemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01133210, the US trial registry maintained by the National Library of Medicine. NCT01133210 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.